Posted inDiabetes & Endocrinology Gastroenterology news
Combination Therapy with GLP-1 Receptor Agonists and SGLT-2 Inhibitors Reduces Liver and Cardiovascular Risks in MASLD and Type 2 Diabetes
A study reveals that combining GLP-1 receptor agonists with SGLT-2 inhibitors significantly lowers the risk of major adverse liver and cardiovascular outcomes in patients with MASLD and type 2 diabetes compared to monotherapy.
